Trials / NCT05392751
Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa
Terminated Phase 1 / Phase 2 Drug / neuroprotection
Why it stopped: Study terminated by the Sponsor. All study participants completed at least 12 months of safety follow-up instead of 24 mo. The reason for earlier termination was due to a corporate decision; not any safety concerns of EA-2353.
- Sponsor
- Endogena Therapeutics, Inc
- Treatment
- EA-2353
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa, Retinitis Pigmentosa Syndrome
- Ages
- 18 Years to no upper limit
- Enrollment
- 14 participants
- Started
- 2022-06-02
- Main results expected
- 2024-04-24
- Results posted
- Not yet
- Record last updated
- 2024-10-15
What the study is testing
This is an open-label, multiple ascending dose study to evaluate the safety, tolerability, and efficacy of EA-2353 in subjects with RP. Unilateral intravitreal injections (IVT) will be administered into the subject's Study Eye. There will be up to 4 cohorts.
Where it runs
United States (5)
- Endogena Site 005, Miami, Florida
- Endogena Site 003, Ann Arbor, Michigan
- Endogena Site 004, Portland, Oregon
- Endogena Site 002, Dallas, Texas
- Endogena Site 001, McAllen, Texas